Simon McClure, MD
Psychiatry · Bridgeport, WVNPI 1386677813
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 977 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 10.8% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 977 payments — averaging $21.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- Vanda Pharmaceuticals Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Alkermes, Inc.$1K
- plus $10K from 25 others
What the payments were for
- Food & beverage$20,88699%
- Education$3111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 116 | $2,284 |
| Vanda Pharmaceuticals Inc. | 68 | $2,035 |
| Teva Pharmaceuticals USA, Inc. | 113 | $1,935 |
| AbbVie(2 entities) | 129 | $1,912 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 75 | $1,761 |
| Alkermes, Inc. | 39 | $1,400 |
| Takeda Pharmaceuticals U.S.A., Inc. | 65 | $1,293 |
| Sunovion Pharmaceuticals Inc. | 52 | $1,153 |
| Neurocrine Biosciences, Inc. | 40 | $1,068 |
| Supernus Pharmaceuticals, Inc. | 50 | $997 |
| Johnson & Johnson | 27 | $923 |
| Corium, LLC | 33 | $739 |
| Axsome Therapeutics, Inc. | 17 | $722 |
| Lundbeck LLC | 29 | $644 |
| Neos Therapeutics, LP | 26 | $407 |
| Almatica Pharma LLC | 16 | $374 |
| Bausch Health US, LLC | 20 | $340 |
| Jazz Pharmaceuticals Inc. | 16 | $315 |
| Ironshore Pharmaceuticals Inc. | 7 | $224 |
| Eisai Inc. | 10 | $144 |
| Tris Pharma Inc | 5 | $99 |
| E.r. Squibb & Sons, L.L.C. | 3 | $86 |
| Avanir Pharmaceuticals, Inc. | 6 | $85 |
| Noven Therapeutics, LLC | 3 | $56 |
| Merck | 3 | $50 |
| Shire North American Group Inc | 3 | $44 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $29 |
| Adlon Therapeutics L.p. | 2 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Sage Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,500
- LYBALVI$1,398
- LATUDA$583
- ARISTADA INITIO$375
- Fanapt$375
- VRAYLAR$366
- REXULTI$365
- CAPLYTA$348
- Auvelity$244
- SPRAVATO$234
- Jornay PM 20mg capsules (Bottle of 100)$127
- VIVITROL$125
- AUSTEDO$122
- INVEGA TRINZA$122
- INVEGA SUSTENNA$122
How this compares
$21,197 in reported general payments places this provider in the 90th percentile of 177 psychiatry providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 65 | $608,175 |
| RexultiBrexpiprazole | 385 | $602,259 |
| Austedo XrDeutetrabenazine | 33 | $359,305 |
| IngrezzaValbenazine Tosylate | 24 | $226,065 |
| VraylarCariprazine Hcl | 104 | $171,766 |
| Aripiprazole | 1,325 | $162,026 |
| TrintellixVortioxetine Hydrobromide | 253 | $155,185 |
| Invega SustennaPaliperidone Palmitate | 44 | $106,969 |
| LybalviOlanzapine/Samidorphan Malate | 31 | $60,550 |
| Lurasidone Hcl | 192 | $49,029 |
| Abilify MaintenaAripiprazole | 18 | $47,552 |
| Duloxetine Hcl | 1,163 | $35,256 |
| CaplytaLumateperone Tosylate | 20 | $35,215 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 1,006 | $31,083 |
| Vilazodone Hcl | 194 | $28,310 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $1,935 | $967,48098 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $2,284 | $649,810403 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,068 | $226,06524 claims |
| AbbVieVraylar, Savella | $1,912 | $181,643126 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $1,293 | $171,862297 claims |
| Johnson & JohnsonInvega Sustenna | $923 | $106,96944 claims |
| Alkermes, Inc.Lybalvi | $1,400 | $60,55031 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,761 | $35,21520 claims |
| Axsome Therapeutics, Inc.Auvelity | $722 | $22,43726 claims |
| Neos Therapeutics, LPAdzenys Xr-Odt | $407 | $11,14812 claims |
| MerckBelsomra | $50 | $10,12915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 psychiatry providers in West Virginia.
Other psychiatry in Bridgeport
- Muhammad SalmanBridgeport$606
- Melissa MoodyCharleston$1.2M
- April BaisdenScott Depot$775K
- Ryan WakimWheeling$772K
- Daniel ThistlethwaiteSouth Charleston$468K
- Walter ByrdMorgantown$299K
- Fahd MousaCharleston$200K
- Debra StultzBarboursville$173K
- Shahnoor KhanMartinsburg$161K
- Ahmed FaheemBeckley$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.